Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-06-07
2011-06-07
Zeman, Robert A (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S197110, C424S184100, C536S023100, C530S395000
Reexamination Certificate
active
07955605
ABSTRACT:
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype ofStreptococcus pneumoniae(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprisingStreptococcus pneumoniaeserotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
REFERENCES:
patent: 4097666 (1978-06-01), Johnson et al.
patent: 4673574 (1987-06-01), Anderson
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5097020 (1992-03-01), Anderson
patent: 5153312 (1992-10-01), Porro
patent: 5306492 (1994-04-01), Porro
patent: 5623057 (1997-04-01), Marburg
patent: 6620928 (2003-09-01), Besemer
patent: 7582459 (2009-09-01), Hamidi
patent: 7588765 (2009-09-01), Porro
patent: 7709001 (2010-05-01), Hausdorff
patent: 2001/0048929 (2001-12-01), Chong et al.
patent: 2003/0147922 (2003-08-01), Capiau
patent: 2003/0180316 (2003-09-01), Boutriau et al.
patent: 2004/0213817 (2004-10-01), Miller et al.
patent: 2006/0228380 (2006-10-01), Hausdorff et al.
patent: 2007/0110762 (2007-05-01), Jessouroun et al.
patent: 2007/0184071 (2007-08-01), Prasad
patent: 2007/0231340 (2007-10-01), Hausdorff et al.
patent: 2009/0130137 (2009-05-01), Hausdorff
patent: 0 477 508 (1992-04-01), None
patent: 0 497 525 (1992-05-01), None
patent: 1 0356 137 (2000-09-01), None
patent: 2 857 364 (2005-01-01), None
patent: A-06-340550 (1994-12-01), None
patent: A-2002-503705 (2002-02-01), None
patent: A-2002-526082 (2002-08-01), None
patent: WO98/51339 (1998-11-01), None
patent: WO 99/42130 (1999-08-01), None
patent: WO 00/17370 (2000-03-01), None
patent: WO03/051392 (2003-06-01), None
patent: WO2004/011027 (2004-02-01), None
patent: WO 2004/011027 (2004-02-01), None
patent: WO 2004/067574 (2004-08-01), None
patent: WO 2005/058940 (2005-06-01), None
patent: WO 2006/110381 (2006-10-01), None
Rexroad et al 2002 Cell Preservation Technology vol. 1 No. 2 pp. 91-104.
Black, S., et al., “Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children,”Pediatr Infect Dis J, 2000, pp. 187-195, vol. 19.
Black S., et al., “Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine,”Pediatr Infect Dis J2001, pp. 1105-1107, vol. 20.
Block, S.L., et al., “Pneumococcal serotypes from acute otitis media in rural Kentucky,”Pediatr Infect Dis J, 2002, pp. 859-865, vol. 21.
Buckingham, S.C., et al., “Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001,”Pediatr Infect Dis J, 2003, pp. 499-504, vol. 22.
Butler J., et al., “Serotype distribution ofStreptococcus pneumoniaeinfections among preschool children in the United States, 1978-1994,”J Infect Dis1995, pp. 885-889, vol. 171.
Byington, C., et al., “An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations,”Clin Infect Dis, 2002, pp. 434-440, vol. 34.
Choo, S., et al., “Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine Administered Combined with aHaemophilus influenzaetype b conjugate vaccine in United Kingdom Infants,”Pediatr Infect Dis J, 2000, pp. 854-862, vol. 19.
Eltringham, G., et al., “Culture-Negative Childhood Empyeme is Usually Due to Penicillin-SensitiveStreptococcus pneumoniaeCapsular Serotype 1,”J. Clin Micr, 2003, pp. 521-522, vol. 41.
Eskola. J., et al., “Efficacy of a pneumococcal conjugate vaccine against acute otitis media,”N Engl J Med, 2001, pp. 403-409, vol. 344.
Fagan, R.L., “The epidemiology of invasive pneumococcal disease in children in Far North Queensland,”J. Paediatr Child Health, 2001, pp. 571-575, vol. 37.
Giebink, G.S., et al., “Immunogenicity and efficacy ofStreptococcus pneumoniaepolysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model,”J Infect Dis, 1996, pp. 119-127, vol. 173.
Hausdorff W.P, et al., “Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I,”Clin Infect Dis2000, pp. 100-121, vol. 30.
Hausdorff W.P, et al., “The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part I,”Clin Infect Dis2000, pp. 122-140, vol. 30.
Hausdorff, W.,et al., “Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children,”Lancet, 2001, pp. 950-952, vol. 357.
Hausdorff, W.P., et al., “Multinational study of pneumococcal serotypes causing acute otitis media in children,”Pediatr Infect Dis J, 2002, pp. 1008-1016, vol. 21.
Hausdorff., W.P., et al., “Invasive Pneumococcal Disease in Children: Geographic and Temporal Variations in Incidence and Serotype Distribution,”Eur. J. Pediatr., 2002, pp. 135-139, vol. 161 (Suppl. 2).
Hausdorff., W.P., et al., “Epidemiological Differences Among Pneumococcal Serotypes,”Lancet Infect. Dis., 2005, pp. 83-93, vol. 5(2).
Hofmann J., et al., “The prevalence of drug-resistantStreptococcus pneumoniaein Atlanta,”N Engl J Med1995, pp. 481-486, vol. 333.
Jakobsen, H., et al., “Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity in serotype 19A in a murine pneumococcal pneumonia model,”Infect Immun,2003, pp. 2956-2959, vol. 71.
Joloba M.L., et al., “Pneumococcal conjugate vaccine serotypes ofStreptococcus pneumoniaeisolates and the antimicrobial susceptibility of such isolates in children with otitis media,”Clin Infect Dis2001, pp. 1489-1494, vol. 33.
Kertesz D.A., et al., “InvasiveStreptococcus pneumoniaeinfection in Latin American children: results of the Pan American Health Organization Surveillance Study,”Clin Infect Dis, 1998, pp. 1355-1361, vol. 26.
Klugman, K.P., et al., “A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection,”N Engl J Med, 2003, pp. 1341-1348, vol. 349.
Mbelle, N., et al., “Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine,”Journal of Infectious Diseases, 1999, pp. 1171-1176, vol. 180.
Nahm, M.HH, et al., “Identification of cross-reactive antibodies with low opsonophagocytic activity forStreptococcus pneumoniae,” J Infect Dis, 1997, pp. 698-703, vol. 176.
O'Brien, K.L., et al., “Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial,”Lancet,2003, pp. 366-361, vol. 362.
Penn, R.L., et al., “Antibody responses in adult volunteers to pneumococcal polysaccharide types 19F and 19A administered singly and in combination,”Infect Immun,1982, pp. 1261-1262, vol. 36.
Robbins, J.B., et al., “Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups,”J Infect Dis, 1983, pp. 1136-1159., vol. 148.
Robinson K.A., et al.,“Epidemiology of invasiveStreptococcus pneumoniaeinfections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era,”JAMA2001, pp. 1729-1735, vol. 285.
Rudolph, K.M., et al, “Serotype distribution and antimicrobial resistance
Archie Nina A
Ropes & Gray LLP
Wyeth LLC
Zeman Robert A
LandOfFree
Multivalent pneumococcal polysaccharide-protein conjugate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent pneumococcal polysaccharide-protein conjugate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent pneumococcal polysaccharide-protein conjugate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621518